Biopsy tissue was sent for genomic profiling (FoundationOne, Foundation Medicine) that identified the NCOA4-RET fusion and, based on the breakpoints, was found to join exons 1−7 of NCOA4 in frame  with exons 12−19 of RET. Histology of the recurrent breast cancer tissue revealed a papillary architecture which is characteristic of RET fusion-positive thyroid cancers. Here, RET is linked to thyroid cancer.